May 7, 2024
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer(Securities Code: 4582)

Revision to Earnings Forecast for FY 2024

TOKYO, Japan, May 7, 2024 – SymBio Pharmaceuticals Limited (Headquarters: Tokyo, “SymBio” orthe “Company”) today announced that the Company’s Board of Directors today approved the following
revision to the earnings forecast for fiscal year ending December 31, 2024. The earnings forecast waspreviously announced on December 8, 2023. The revision reflects the Company’s current performancetrends and outlook.

1. Revision to Earnings Forecast for FY 2024 (January 1, 2024 to December 31, 2024)
ProfitOperating

Ordinary

ProfitProfitYen millions

Yen millions

Yen millions

Yen millions

Yen

Previous Forecast (A)3,641(2,837)(2,867)(2,870)(71.93)

Revised Forecast (B)2,623(3,702)(3,524)(3,628)(84.15)Difference (B-A)(1,018)

(865)

(657)

(758)

－

Percentage Change (%)(28.0)(30.5)(22.9)(26.4)－5,589

(811)

(736)

(1,962)(49.19)Net Sales

attributable toowners of parentEarnings
per share[Reference] Prior Year
Results (FY 2022)

2. Reasons for changes
The NHI price of TREAKISYM® has declined due to a reduction in the premium for new drug creation
following the launch of generic drug products. As a result, sales in the first quarter were lower than
expected due to the impact of inventory adjustments prior to the application of the new drug price whichbecame effective in April 2024.
A downward trend in prescriptions per case of malignant lymphoma due to the epidemic in infectious
diseases is expected to continue, and the market share of generic drug products is expected to gradually
increase going forward. As it is expected to be difficult to recover the sales decline of the first quarter
from the second quarter onward, the Company has lowered its sales forecast for the fiscal year ending
1

December 31, 2024, by 1,018 million yen (a decrease of 28.0%) to 2,623 million yen.
Although R&D expenses are expected to be 3,409 million yen (up 201 million yen from the previousforecast) due to steady progress in clinical trials, selling, general and administrative expenses weregenerally in line with the forecast due to a review of other expenses. As a result of the impact of thesignificant decrease in gross profit due to the decline in net sales, the Company has revised its forecasts
for operating loss of 3,702 million yen (a reduction of 865 million yen compared to the previous forecast),
ordinary loss of 3,524 million yen (a reduction of 657 million yen compared to the previous forecast),
and net loss attributable to owners of the parent of 3,628 million yen (a reduction of 758 million yen
compared to the previous forecast).
The assumption of the foreign exchange rate has been changed from 141.83 yen per U.S. dollar to 151.41 yen per U.S.
dollar.
*Earnings forecasts, financial projections, and other forecasts or forward-looking statements containedin this disclosure have been prepared by the Company at its discretion and based on information
available to the Company as of the date of this disclosure. Actual results may vary materially from theinformation contained in this disclosure as a result of changes to business, economic, financial, or otherassumptions and conditions.
[Contact]
Investor Relations
Tel: +81(0)3 5472 1125

2